Form 4: Bioadaptives Director Receives Stock

Bioadaptives, Inc. director Mark P. Frissora received Series D Convertible Preferred Stock as compensation for board services.

Summary

• Mark P. Frissora, a Director at Bioadaptives, Inc., was issued 4,386 shares of Series D Convertible Preferred Stock on April 1, 2026.
• This issuance is compensation for his board services under an agreement dated February 3, 2025.
• The preferred stock is convertible into common stock at a 100:1 ratio, subject to a 4.9% beneficial ownership limitation.
• Conversion is restricted for six months post-issuance, except in cases of liquidation.
• Each preferred share carries 100 votes on matters of the Issuer.
• The right to convert does not expire.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director compensation in the form of equity aligns incentives with the company's performance.
• The convertible preferred stock provides potential upside through conversion into common stock.
• The voting rights attached to the preferred stock give the holder influence on corporate matters.

Negatives

• The conversion of preferred stock into common stock is subject to a 4.9% beneficial ownership limitation, potentially capping the upside for the holder.
• There is a six-month lock-up period on conversion, delaying the realization of common stock benefits.

Risks

• The value of the Series D Convertible Preferred Stock is tied to the future performance and stock price of Bioadaptives, Inc.
• Potential dilution to existing common stockholders if a significant portion of the preferred stock is converted.

Future Outlook

The future outlook for the Series D Convertible Preferred Stock depends on the company's performance and the market value of its common stock, as well as the potential for conversion after the six-month restriction.

Industry Context

StockSavvy.ai notes that the issuance of convertible preferred stock as compensation for board services is a common practice in the biotechnology and technology sectors, aiming to attract and retain experienced directors by aligning their interests with long-term shareholder value.

Related Party Transactions

• The issuance of Series D Convertible Preferred Stock to Director Mark P. Frissora for board services is a related party transaction.

Stakeholder Impact

• Shareholders: Potential for dilution if preferred stock is converted, but also potential for increased director engagement and oversight leading to improved company performance.
• Employees: Indirect impact through potential company growth and value appreciation.
• Management: Alignment of director incentives with company success.

Next Steps

• Mark P. Frissora may convert his Series D Convertible Preferred Stock into common stock after October 1, 2026, subject to beneficial ownership limitations.
• The company's performance will dictate the value of the convertible preferred stock and the potential for conversion.

Key Dates

Keywords

SEC Form 4, Bioadaptives, Inc., BDPT, Mark P. Frissora, Director Compensation, Convertible Preferred Stock, Equity Award, Beneficial Ownership